Antibody selection is critical to the analytical performance, consistency, and long term manufacturability of Lateral Flow Assays. Our antibody screening service supports early decision making by enabling evaluation of broad candidate panels before committing to full assay development or scale up.

​

The service at Fleet Bioprocessing Ltd. is well suited to programmes requiring assessment of large antibody panels using limited material. By working effectively with very small antibody quantities, extensive candidate sets can be evaluated without restriction from supply constraints or material costs, enabling a comprehensive, data led approach to antibody selection and increasing confidence in the selected pairing.

​

Antibodies are assessed in assay formats that reflect the physical and biochemical conditions of lateral flow devices, ensuring relevance to downstream development. This allows early identification of candidates with suitable binding behaviour, signal performance, and membrane compatibility, reducing development risk and avoiding costly rework.

​

By combining efficient material use with broad candidate evaluation, the screening process accelerates development while maintaining a focus on performance, reproducibility, and scalability.

​

Following initial antibody selection, one or more Proof of Concept Lateral Flow Assay formats can be constructed to assess suitability for the intended application.

​

Contact us to discuss how our antibody screening service can support your Lateral Flow Assay development.

​

​